DO-BO

How can we navigate the complexities of Medical Devices Market Access in Spain, Sergio Gil?

Are you intrigued by the pulsing heart of Spain’s healthcare sector, or are you considering navigating the vibrant market of medical devices in Spain? Dive into our latest Market Access podcast episode where we unravel the complexities and dynamism of Spain’s medical landscape.

Join us as Sergio Gil, a seasoned veteran with over three decades in the medical device industry, shares his invaluable insights. From understanding Spain’s unique regional healthcare powers to decoding the reimbursement conundrums, Sergio illuminates the path to successful market entry and what makes Spain not just culturally, but commercially captivating.

Here’s a sneak peek at what you’ll discover:

  • The striking differences between the pharmaceutical and medical device sectors in Spain.
  • An insider’s guide to Spain’s decentralized healthcare approach and how it impacts market access.
  • Key strategies for companies aiming to penetrate the Spanish market – straight from the expert.
  • The burgeoning world of digital health in Spain and the emerging trends to watch out for.

Whether you’re a startup eyeing Spain for your next big launch or a seasoned player looking to deepen your market footprint, this episode is packed with strategic gold.

Related

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]